NEW YORK, Aug. 11, 2026 (GLOBE NEWSWIRE) -- etoro Group Ltd. (“etoro”, or the “Company”) (NASDAQ: ETOR), the trading and investing platform, announced today that it has entered into an ...
The Company expects to initiate its Phase 1 study of PRT13722, a first-in-class highly-selective oral KAT6A degrader in HR+ breast cancer in the fourth quarter Presented preclinical data demonstrating ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results